Skip to main content
IMMUNIC, INC. logo

IMMUNIC, INC. — Investor Relations & Filings

Ticker · IMUX ISIN · US4525EP1011 LEI · 549300R5T12FW5MEQB20 US Professional, scientific and technical activities
Open in API
Filings indexed 786 across all filing types
Latest filing 2026-04-30 Regulatory Filings
Country US United States of America
Listing US IMUX

About IMMUNIC, INC.

https://imux.com/

Immunic, Inc. is a clinical-stage biopharmaceutical company focused on developing a pipeline of selective, orally administered, small molecule therapies for chronic inflammatory and autoimmune diseases. The company's mission is to create high-quality, oral treatment options that offer comprehensive therapeutic efficacy with favorable safety and tolerability profiles. Its clinical development programs target conditions with significant unmet medical needs, including multiple sclerosis and celiac disease, aiming to provide patients with convenient and effective solutions to manage debilitating symptoms and improve their quality of life.

Recent filings

Filing Released Lang Actions
Immunic to Participate in Investor and Medical Conferences in May
Regulatory Filings
2026-04-30 English
8-K - IMMUNIC, INC. (0001280776) (Filer)
Regulatory Filings
2026-04-28 English
Immunic Appoints Accomplished Biopharmaceutical Executive Michael A. Panzara, M.D., M.P.H., as Chief Medical Officer
Board/Management Information Classification · 1% confidence The document is a corporate press release announcing the appointment of Michael A. Panzara as Chief Medical Officer, detailing succession, responsibilities, and executive background. It clearly relates to a change in senior management. Therefore, it fits the Board/Management Information category.
2026-04-28 English
8-K - IMMUNIC, INC. (0001280776) (Filer)
Regulatory Filings
2026-04-23 English
Immunic, Inc. Announces 1-for-10 Reverse Stock Split
Share Issue/Capital Change Classification · 1% confidence The document is a corporate press release announcing a 1-for-10 reverse stock split of Immunic’s common stock, i.e., a capital structure change (share consolidation). This is not a fundraising announcement, legal proceeding, dividend notice, or management change, but rather a stock split. Therefore it falls squarely under Share Issue/Capital Change (SHA).
2026-04-23 English
10-K/A - IMMUNIC, INC. (0001280776) (Filer)
Annual Report
2026-04-22 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.